Back to results
US 2024/0174668 A1Published application
Pyridazine compounds for inhibiting nlrp3
AssigneeVentus Therapeutics U.S., Inc.
InventorsStéphane DORICH, Jason BURCH, Miguel ST-ONGE, Amandine CHEFSON, Alexandre CÔTÉ, Ramsay BEVERIDGE, Stéphane CIBLAT
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):
Claims21
-42. (canceled)
The compound of claim 3, wherein R2 and R3 are joined to form:
- to provide a compound of Formula (II-h):
- or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof;
- wherein R2a is H.
A compound of Formula (II):
- or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:
- Y is phenyl independently substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, halo, cyano, or —R4OR5, wherein at least one substitution is substituted at the para-position of the phenyl ring;
- R1 is:
- (i) C1-C6 alkyl substituted with an optionally substituted 3- to 8-membered heterocycloalkyl, an optionally substituted C5-C10 aryl, or an optionally substituted 5- to 9-membered heteroaryl;
- or
- (ii) 3- to 8-membered heterocycloalkyl optionally substituted with one or more halo, —R4OR5, an optionally substituted 3- to 8-membered heterocycloalkyl, an optionally substituted C5-C10 aryl, or an optionally substituted 5- to 9-membered heteroaryl;
- or
- (iii) R1 is 5- to 9-membered heteroaryl optionally substituted with one or more halo, —R4OR5, an optionally substituted 3- to 8-membered heterocycloalkyl, an optionally substituted C5-C10 aryl, or an optionally substituted 5- to 9-membered heteroaryl;
- R2 and R3, together with the atoms to which they are attached, form a 5- to 9-membered heteroaryl optionally substituted with one or more R2a;
- R2a is hydrogen, C1-C6 alkyl, halo or C1-C6 haloalkyl;
- R4 is absent, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
- and
- R5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C5-C10 aryl, or 5- to 9-membered heteroaryl.
10 more elements
A compound of Formula (II):
- or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:
- Y is phenyl independently substituted with one or more C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, halo, cyano, or —R4OR5, wherein at least one substitution is substituted at the para-position of the phenyl ring;
- R1 is tetrahydrofuranyl optionally substituted with one or more halo, C1-C6 alkyl, or —R4OR5;
- R2 and R3, together with the atoms to which they are attached, form:
- R4 is absent;
- and
- R5 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C5-C10 aryl, or 5- to 9-membered heteroaryl.
4 more elements
Dependencies are inferred from the claim text.